Advertisement

Picture Berlin Partner Berlin-Brandenburg Healthcare Industries Cluster 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 18 19 20 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Novartis–Science 37: clinical research, 201803– collab 3y expansion up to 10 decentralised clinical trials 2018-03-07
Ventech–SEVERAL: investment, 201803 first closing €140m of Ventech Capital V fund with €200m target size 2018-03-07
Magenta Therapeutics–Heidelberg Pharma: antibody-drug conjugates, 201803– collab developm of ADCs for bone marrow transplant using ATAC platform 2018-03-05
abcr GmbH–Enzymicals: enzymes, 201803– collab distribution expansion ww catalogue sale of selected enzymes + enzyme-produced chemicals 2018-03-01
Affiris–PR&D: public relations, 201803 service existent by PR&D – Public Relations for Research & Education 2018-03-01
BioMedPartners–SEVERAL: investment, 201805 final closing CHF25m of BioMedInvest III fund bringing total to CHF100m 2018-03-01
Heidelberg Pharma–MC Services: public relations, 201803 service existent by MC Services 2018-03-01
Heidelberg Pharma–Univ Texas: personalised medicine, 201803– license for Dx + Tx of cancer patients w RNA polymerase II deletion 2018-03-01
R-Biopharm–Bosch: molecular diagnostics, 201803– collab €na developm tests for Vivalytic platform + sale of system with tests by R-Biopharm 2018-03-01
Berlin Cures–Russo Partners: public relations, 201802 service existent by Russo Partners 2018-02-26
Bruker–Evosep: liquid chromatography, –201802 collab product integration of timsTOF Pro MS + Evosep One LC for HT clinical proteomics 2018-02-26
Xencor–JSR Corp: cell line development, 201802– four commercial licenses to use Selexis’ SUREtechnology for developm of bispecific antibodies 2018-02-26
IRM² Infrarot Mikroskopie und Messtechnik GmbH–Bruker: investment, 201802 acquisition €na of IRM² by Bruker 2018-02-22
Aimmune Therapeutics–Nestlé: investment, 201802–201803 public offering totalling $202.4m incl $30m from existing investor Nestlé Health Science 2018-02-20
Aimmune Therapeutics–SEVERAL: investment, 201802–201803 public offering $176m+$26.4m net $190m with 5.5m+825k shares common stock at $32/share 2018-02-20
Cullinan Oncology–MAB Discovery: antibody cancer drug, 201802– collab developm of MAbs based on MAB Discovery’s discovery platform 2018-02-20
Gain Therapeutics–SEVERAL: investment, 201802 investment spin-off of Minorix’ SEE-Tx platform as Gain Therapeutics with Swiss investors + TiVenture 2018-02-20
ABAC Therapeutics–SEVERAL: investment, 201802 financing round Series A €16m led by Pontifax + incl GHSF + Caixa Capital Risc + Debiopharm + Ferrer 2018-02-15
Addex–SEVERAL: investment, 201802–201803 private placement CHF40m with 12.78m new shares at CHF3.13/share plus 0.4 warrants at CHF3.43 2018-02-15
Flatiron Health–Roche: investment, 201802–201804 acquisition $1.9b of remaining 87.4% not already owned by Roche 2018-02-15
Mologen–SEVERAL: investment, 201802–201803 capital increase €4.99m with 2.36m new shares at €2.12/share to existing + new investors 2018-02-15
Pieris–SEVERAL: investment, 201802 public offering $50.6m with 5.5m+825k common shares at $8/share 2018-02-13
Swiss Medical Imaging Investment–RAD-x: investment, 201802 acquisition of SMII by RAD-x 2018-02-13
Affimed–SEVERAL: investment, 201802 public offering $26.5m ($24.5m net) with 12.5m+1.725m common shares at $2/share 2018-02-12
Lonza–Kirkstall: cell culture system, 201802– collab ww marketing + distribution of Quasi Vivo System by Lonza 2018-02-12
Pieris–Trophic Communications: public relations, 201802 service existent media relations by Trophic 2018-02-09
Seattle Genetics–Pieris: cancer immunotherapy, 201802– collab $30m upfront + $1.2b milestones + royalties developm antibody-anticalin fusion proteins 2018-02-09
Pfizer–Genedata: bioinformatics, 201802– supply license for Genedata Bioprocess enterprise platform to Pfizer Inc 2018-02-08
Thermo Fisher–Endress+Hauser: lab automation, 201802 collab product integration of AJ’s CyBio FeliX system in cell-free DNA extraction device 2018-02-07
Servier–ImmunoQure: therapeutic antibodies, 201802– collab developm of INF-alpha human autoantibody for autoimmune diseases 2018-02-06
Faron Pharmaceuticals–Lyomark Pharma: Traumakine, 201802– supply contract manfucturing by Lyocontract GmbH 2018-02-05
Faron Pharmaceuticals–Rentschler: Traumakine, 201802 supply existent contract manfucturing by Rentschler Biopharma SE 2018-02-05
TraitGenetics–SGS: investment, 201802 acquisition of TraitGenetics GmbH by SGS 2018-02-02
Cytosurge–Lab Automation Network: cell analysis technology, 201802– collab product integration to offer automated single-cell biology applications 2018-02-01
REPO-TRIAL project–Biocrates: drug respositioning, 201802–202301 collab Biocrates is industry member of Horizon 2020 project 2018-02-01
REPO-TRIAL project–EU (govt): grant, 201802–202301 Horizon 2020 grant €5.6m for in silico trial-based drug repositioning 2018-02-01
REPO-TRIAL project–HM Pharma Consultancy: drug respositioning, 201802–202301 collab HMPC is industry member of Horizon 2020 project 2018-02-01
REPO-TRIAL project–SomaLogic: drug respositioning, 201802–202301 collab SomaLogic UK is industry member of Horizon 2020 project 2018-02-01
Silvacx–Merck (DE): nanoparticle technology, 201802– license excl to Silvacx delivery technology for cancer immunotherapy 2018-02-01
Silvacx–North Rhine-Westphalia (govt): grant, 201802– r+d grant €1.93m 3 years to develop Silvacx technology 2018-02-01
Biotest–Credit Suisse: financial services, 201704 supply service financial advisor with regard to sale of Biotest AG to Ceat Group (CN) 2018-01-31
Immunicum–Trophic Communications: public relations, 201801 service existent IR + media relations EU + US by Trophic 2018-01-31
STAT-Diagnostica–Qiagen: investment, 201801 acquisition $147m upfront cash + $44m milestones of STAT-Dx by Qiagen 2018-01-31
eTherapists–Creathor Ventures: investment, 201801 financing round 7-digit € for Humanoo.com from Creathor + DvH Ventures et al 2018-01-30
eTherapists–SEVERAL: investment, 201801 financing round 7-digit € for Humanoo.com from Creathor + DvH Ventures et al 2018-01-30
Helsinn–Scientific Centre of Monaco: cancer drug, 201801– collab research new pharmacological inhibitors for clear cell renal cell carcinoma 2018-01-30
Ablynx–Sanofi: investment, 201801–201806 acquisition recommended cash tender offer €3.9b with €45/share 2018-01-29
Clariant–SABIC: investment, 201801 acquisition 24.99% shareholding by SABIC via acquisition of shares previously held by White Tale + 40 North 2018-01-25
Topas Therapeutics–Univ Hamburg: anti-inflammatory drugs, 201801– collab Topas excl translational partner for liver inflammation CRC at UKE 2018-01-25
ImmuPharma–SEVERAL: investment, 201801 placing £10m of 6.945m new ordinary shares at 144p/share 2018-01-24
Nebion–Qlucore: genomic software tools, 201801– collab integration of Qlucore Omics Explorer s/w + Genevestigator s/w for gene expression analysis 2018-01-24
Novartis–Spark Therapeutics: voretigene neparvovec, 201801– license ww outside US to develop + register + commerc gene therapy Luxtarna 2018-01-24
High-Tech Gründerfonds–Dräger: investment, 201801 investment of Dräger in HTGF III Fund 2018-01-23
Juno Therapeutics–Celgene: investment, 201801–201803 acquisition cash tender offer $9b net of cash + shares already owned by Celgene $87/share 2018-01-22
Novartis–Biocon: biosimilars, 201801– collab strategic ww excl developm + production + comercialisation Sandoz + Biocon 2018-01-18
Cellnovo–Flextronics: contract manufacturing, 201801 supply existent production of Cellnovo Diabetes Monitoring System + Cartridges by Flex 2018-01-17
Eximmium–Helmholtz: investment, 201801 seed funding €250k from Helmholtz Enterprise + Helmholtz Zentrum München at spin off of Eximmium 2018-01-17
Sartorius–Synpromics: genomic technology, 201801 collab existent with Sartorius Stedim Cellca 2018-01-17
Owkin–SEVERAL: investment, 201801 financing round Series A $11m led by Otium Venture + incl Cathay Innovation + Plug and Play + NJF Capital 2018-01-16
Intelligent Pharma–Mind the Byte: investment, 201801 acquisition €na 100% of Intelligent Pharma by Mind the Byte 2018-01-11
Mind the Byte–SEVERAL: investment, 201801– financing round €3m (1/3 of company) to finance acquisition of Intelligent Pharma PLANNED 2018-01-11
Structural Genomics Consortium–Enamine: chemical compound libraries, 201801– supply new generation of Diamond-SGC-iNEXT (DSI) Poised Library 2018-01-10
BeiGene–Boehringer: biopharmaceuticals, 201801– supply manufacturing of tislelizumab by Boehringer in Shanghai 2018-01-09
BioNTech–Scancell: cancer immunotherapy, 201801– collab research using Moditope platform w excl license option for BioNTech 2018-01-09
General Electric–Roche: diagnostics, 201801– collab developm integrated digital + IVD + in vivo diagnostics platform for oncology + critical care 2018-01-08
Indivumed–EU (govt): credit, 201801– EIB/EFSI loan €40m to create Global Cancer Database Solution 2018-01-08
TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share 2018-01-05
BioNTech–Fidelity: investment, 201801 financing round Series A totalling $270m incl new + co-investor Fidelity Management & Research 2018-01-04
BioNTech–Invus Group: investment, 201801 financing round Series A totalling $270m incl new + co-investor Invus 2018-01-04
BioNTech–Janus Henderson: investment, 201801 financing round Series A totalling $270m incl new + co-investor Janus Henderson Investors 2018-01-04
BioNTech–Redmile Group: investment, 201801 financing round Series A totalling $270m incl new + lead investor Redmile Group LLC 2018-01-04
BioNTech–SEVERAL: investment, 201801 financing round Series A $270m led by new investor Redmile Group LLC 2018-01-04
BioNTech–Strüngmann Group: investment, 201801 financing round Series A totalling $270m incl returning co-investor Strüngmann Family Office 2018-01-04
CureVac–Arcturus Therapeutics: mRNA therapeutics, 201801– strategic collab for lipid-mediated mRNA drugs using RNAoptimizer + LUNAR system 2018-01-04
CureVac–BMC Communications: public relations, 201801 service existent by BMC 2018-01-04
Enterome–BPCE: investment, 201801 financing round Series D totalling €32m incl existing investor Seventure + Health for Life Capital 2018-01-04
Enterome–Lundbeck: investment, 201801 financing round Series D totalling €32m incl existing investor LundbeckFonden Ventures 2018-01-04
Enterome–Nestlé: investment, 201801 financing round Series D totalling €32m incl existing investor Nestlé Health Science 2018-01-04
Enterome–SEVERAL: investment, 201801 financing round Series D €32m incl Seventure + Health for Life Capital + Lundbeck Fonden + Omnes Capital et al 2018-01-04
Miracor–SEVERAL: investment, 201801 financing round Series D €25m incl equity + debt + cash advance grant from Walloon govt 2018-01-04
Oculis–Bay City Capital: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Bay City Capital 2018-01-04
Oculis–Brunnur Ventures: investment, 201801 financing round Series B totalling CHF20m incl existing + co-investor Brunnur Ventures 2018-01-04
Oculis–Huntsworth: public relations, 201801 service existent by Citigate Dewe Rogerson 2018-01-04
Oculis–Nan Fung: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Pivotal BioVenture Partners 2018-01-04
Oculis–Novartis: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Novartis Venture Fund 2018-01-04
Oculis–SEVERAL: investment, 201801 financing round Series B CHF20m led by Bay City Capital + NVF + Pivotal BioVenture Partners 2018-01-04
Oculis–Silfurberg: investment, 201801 financing round Series B totalling CHF20m incl existing + co-investor Silfurberg 2018-01-04
Rewind Therapeutics–Boehringer: investment, 201801 financing round Series A totalling €15.2m incl co-lead investor BIVF 2018-01-04
Rewind Therapeutics–Flanders (govt): investment, 201801 financing round Series A totalling €15.2m incl co-lead investor PMV 2018-01-04
Rewind Therapeutics–Merck (DE): investment, 201801 financing round Series A totalling €15.2m incl co-lead investor Merck Ventures 2018-01-04
Rewind Therapeutics–SEVERAL: investment, 201801 financing round Series A €15.2m led by BIVF + Merck Ventures + PMV 2018-01-04
Rewind Therapeutics–Univ Leuven: investment, 201801 financing round Series A totalling €15.2m incl co-investors KU Leuven CD3 + KU Leuven GFF 2018-01-04
Themis Bioscience–SEVERAL: investment, 201801 financing round Series C €10m led by new investor GHIF 2018-01-04
Themis Bioscience–Trophic Communications: public relations, 201801 service existent by Trophic 2018-01-04
BASF–Biocrates: investment, 201801 acquisition of Metanomics Health GmbH by Biocrates from BASF Plant Science GmbH 2018-01-03
Biocrates–BASF: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund 2018-01-03
Biocrates–MIG Fonds: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund 2018-01-03
Biocrates–SEVERAL: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund 2018-01-03
Biocrates–Xolaris Service KVG: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund 2018-01-03
Centogene–MacDougall Biomedical Communications: public relations, 201801 service existent by MacDougall 2018-01-03
next pagenext page 1 2 3 ... 18 19 20 ... 29 30 31  next pagenext page



Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] No Content Marketing 650x80px

» top